Abstract
Vitamin K antagonists such as acenocoumarol and warfarin are usually indicated for the treatment of Atrial Fibrillation (AF). The Therapeutic Range Time (TRT) is a quality of treatment indicator. Values greater than 65% are associated with significantly lower stroke and bleeding rates. Proper pharmaceutical care improves TRT. To evaluate the impact of pharmaceutical care in patients with AF treated with acenocoumarol. We studied 41 patients using acenocoumarol for AF aged 71 ± 11 years (43% women). They received pharmaceutical counseling during 12 weeks. TRT was calculated retrospectively for the year before counseling and prospectively during the intervention period. After receiving pharmaceutical counseling TRT improved from 29% at baseline to 46% at the end of the intervention (p < 0.01). After pharmaceutical care, the adherence of patients to drug treatment improved from 27% at baseline to 85% at the end of the study. The user satisfaction survey of the pharmaceutical care received showed a high degree of patient satisfaction. Pharmaceutical care in patients with oral anticoagulant treatment improves TRT of anticoagulation. It is accepted and positively evaluated by patients.
Highlights
Vitamin K antagonists such as acenocoumarol and warfarin are usually indicated for the treatment of Atrial Fibrillation (AF)
Aim: To evaluate the impact of pharmaceutical care in patients with AF treated with acenocoumarol
Material and Methods: We studied 41 patients using acenocoumarol for AF aged 71 ± 11 years (43% women)
Summary
Vitamin K antagonists such as acenocoumarol and warfarin are usually indicated for the treatment of Atrial Fibrillation (AF). Material and Methods: We studied 41 patients using acenocoumarol for AF aged 71 ± 11 years (43% women) They received pharmaceutical counseling during 12 weeks. The adherence of patients to drug treatment improved from 27% at baseline to 85% at the end of the study. Conclusions: Pharmaceutical care in patients with oral anticoagulant treatment improves TRT of anticoagulation. It is accepted and positively evaluated by patients. Otro estudio realizado por el Servicio de Salud Metropolitano Occidente (SSMOc) en 2017, mostró una mediana de 50% para el TRT en pacientes con FA y un promedio de 301,6 días días para llegar al rango terapéutico deseado[5]. Varios estudios recientes han demostrado un importante aporte de la atención farmacéutica en el tratamiento anticoagulante oral con AVK, aumentando el %INR en rango terapéutico y el TRT2,13-23.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
